Merrimack Pharmaceuticals, Inc.
MACK · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $213,022 | $192,277 | $176,578 | $175,816 |
| - Cash | $234,160 | $5,989 | $6,083 | $10,131 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$21,138 | $186,288 | $170,495 | $165,685 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$669 | $262 | -$531 | -$569 |
| % Margin | – | – | – | – |
| Net Income | -$23,630 | -$240 | -$279 | -$391 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.64 | -0.017 | -0.02 | -0.027 |
| % Growth | -9,720.4% | 14.4% | 28.8% | – |
| Operating Cash Flow | -$1,314 | -$295 | -$203 | -$668 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1,314 | -$295 | -$203 | -$668 |